BioVersys AG (XSWX:BIOV) Issuance of Debt: CHF6.93 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.60
View Full Analysis

What is BioVersys AG Issuance of Debt?

BioVersys AG XSWX:BIOV -2.92% 4 Issuance of Debt is CHF6.93 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Issuance of Debt for the six months ended in Dec. 2025 was CHF6.93 Mil.

BioVersys AG's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was CHF6.93 Mil.

BioVersys AG Issuance of Debt Related Terms

BioVersys AG Issuance of Debt Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Issuance of Debt Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Issuance of Debt
0.00 6.93

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Issuance of Debt 0.00 0.00 0.00 6.93
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF6.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of CHF6.93 Mil mean?
BioVersys AG (XSWX:BIOV) has a Issuance of Debt of CHF6.93 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Issuance of Debt too high?
BioVersys AG's current Issuance of Debt is CHF6.93 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Issuance of Debt compare to VRTX and REGN?
BioVersys AG's Issuance of Debt of CHF6.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on BioVersys AG and its competitors. BioVersys AG's current Issuance of Debt is CHF6.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Issuance of Debt of CHF6.93 Mil. The current Issuance of Debt is CHF6.93 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Issuance of Debt is CHF6.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.60
Price